NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Precipio, Inc. Common Stock (PRPO) Stock Analysis

Precipio, Inc. Common Stock (PRPO) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

PRPO

$27.40

+$1.28 (+4.90%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRPO with… →

PRPO Key Statistics

As of Sep 4, 2026
Trading
Open
$26.11
Previous Close
$26.12
Day's Range
24.48–27.90
52-Week Range
16.00–33.63
Volume
114.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.33
Valuation
Market Cap
$49.05M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
70.26
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.80
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.65
Financials (FY)
Revenue (FY)
$24.05M+29.77%
Net Income (FY)
−$363.00K
Profit marginThe share of revenue left as profit after all costs and taxes.
−4.47%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.79M
1-Year Return
+70.19%
Dividend and dates
Avg Volume
101.98K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PRPO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+19.23%
2025+314.80%
2024−14.77%
2023−41.02%
2022−65.13%
2021−23.67%
2020+0.98%
2019−11.26%
2018−87.17%
2017 (partial year)−86.67%

As of September 4, 2026.

PRPO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$24.05M−$363.00K−1.5%
2024$18.53M−$4.29M−23.1%
2023$15.20M−$5.85M−38.5%
2022$9.41M−$12.20M−129.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$24.05M$10.71M−$1.20M−$363.00K−1.5%
2024$18.53M$7.56M−$4.22M−$4.29M−23.1%
2023$15.20M$6.02M−$7.62M−$5.85M−38.5%
2022$9.41M$2.51M−$12.80M−$12.20M−129.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRPO Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricPRPODiagnostics & Research medianvs median
P/S ratio1.804.9964% below
Profit margin−4.47%0.00%4.5 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Precipio, Inc. Common Stock (PRPO) carries a market capitalisation of $49.05M. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 61 employees.

The 52-week range on file runs from $16.00 to $33.63. PRPO last closed at $27.40 on September 4, 2026. That is +$1.28 (+4.90%) against the previous close. The latest close sits 71.25% above that 52-week low.

Financial Health

In fiscal 2025, Precipio, Inc. Common Stock reported revenue of $24.05M. That is +29.77% against the prior fiscal year, when revenue was $18.53M. The same year closed with a net loss of $363.00K. The reported profit margin is −4.47%. That is 4.5 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −0.65.

Across the 4 fiscal years on file, revenue moves from $9.41M in 2022 to $24.05M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 70.26. Measured against sales, the shares trade at 1.8 times revenue. On price-to-sales that is 63.86% below the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Beta against the wider market is reported at 1.33. Daily returns over the trailing 9 years annualize to a volatility of 195.24%. Over the trailing twelve months the price has returned +70.19%. Measured over 5 years, that is −15.87% a year compounded.

Growth & Income

No dividend is on file for PRPO.

The strongest complete calendar year on file is 2025 at +314.80%; the weakest is 2018 at −87.17%. Of the 8 complete calendar years on file, 2 finished higher. So far in 2026 the price is +19.23%.

Peer Comparison

Precipio, Inc. Common Stock (PRPO) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Precipio, Inc. Common Stock PRPO $49.05M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Precipio, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Precipio, Inc. Common Stock

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

Visit website →